Collegium Pharmaceutical Reports Q3 Revenue Beat Amid Significant Non-GAAP EPS Miss
Collegium Pharmaceutical (COLL) reported third-quarter financial results characterized by a significant miss in earnings alongside a slight revenue beat. While revenue reached $216.3 million, representing a 3.3% year-over-year increase and exceeding expectations by $0.27 million, the company's Non-GAAP EPS of $0.60 fell short of estimates by $1.26. Profitability metrics also showed signs of contraction. Adjusted EBITDA for the quarter was reported at $121.6 million, marking a 9% decline compared to the $133.0 million recorded in the same period last year. The divergence between steady revenue growth and declining earnings suggests rising operational costs or margin pressure.
Tickers: $COLL
Topics: earnings miss EBITDA decrease revenue beat